DeepMed Research

EyePoint Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1987-01-01

Employees: 121

Market Cap: $486.4M

Website: http://www.eyepointpharma.com

Introduction: EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Clinical Trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Phase 3

Recruiting

Conditions: Wet Age Related Macular Degeneration
wAMD

Interventions: Drug: EYP-1901
Drug: Aflibercept (2.0 mg)

First Posted Date: 2024-11-12

Last Posted Date: 2025-05-04

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 400

Registration Number: NCT06683742

Locations: 🇺🇸
Associated Retina Consultans, Gilbert, Arizona, United States
🇺🇸
Associated Retina Consultants - Phoenix, Phoenix, Arizona, United States
🇺🇸
Phoenix Retina Clinical Trials, LLC, Phoenix, Arizona, United States

and more 68 locations

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Phase 3

Recruiting

Conditions: Wet Age Related Macular Degeneration
wAMD

Interventions: Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

First Posted Date: 2024-10-31

Last Posted Date: 2025-05-04

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 400

Registration Number: NCT06668064

Locations: 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Retina Partners of Northwest Arkansas, Springdale, Arkansas, United States
🇺🇸
California Retina Consultants, Bakersfield, California, United States

and more 76 locations

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Aflibercept 2Mg/0.05Ml Inj,Oph
Drug: EYP-1901

First Posted Date: 2023-10-25

Last Posted Date: 2025-03-04

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 27

Registration Number: NCT06099184

Locations: 🇺🇸
EyePoint Investigative Site, Lynchburg, Virginia, United States

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

Phase 3

Not yet recruiting

Conditions: Cataract

Interventions: Drug: Dexycu
Other: Placebo/Vehicle

First Posted Date: 2022-09-22

Last Posted Date: 2022-09-22

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 150

Registration Number: NCT05550350

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

Phase 3

Withdrawn

Conditions: Cataract

Interventions: Other: Placebo/Vehicle
Drug: Dexycu

First Posted Date: 2022-09-22

Last Posted Date: 2024-04-03

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Registration Number: NCT05550363

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Phase 2

Completed

Conditions: Nonproliferative Diabetic Retinopathy

Interventions: Drug: EYP-1901
Other: Sham IVT

First Posted Date: 2022-05-20

Last Posted Date: 2024-08-27

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 77

Registration Number: NCT05383209

Locations: 🇺🇸
EyePoint Investigative Site, Bellevue, Washington, United States

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Phase 2

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Aflibercept 2Mg/0.05Ml Inj,Oph
Drug: Eyp-1901

First Posted Date: 2022-05-19

Last Posted Date: 2024-08-27

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 160

Registration Number: NCT05381948

Locations: 🇺🇸
EyePoint Investigative Site, Silverdale, Washington, United States
🇺🇸
EyePoint Investigative Sites, Houston, Texas, United States

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Phase 4

Recruiting

Conditions: Cataract

Interventions: Drug: Dexamethasone
Drug: Prednisolone Acetate Ophthalmic

First Posted Date: 2022-01-13

Last Posted Date: 2025-04-03

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT05191706

Locations: 🇺🇸
EyePoint Investigative Site, New York, New York, United States
🇺🇸
EyePoint Investigational Site, Charleston, South Carolina, United States

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

Phase 3

Terminated

Conditions: Uveitis
Uveitis, Posterior
Uveitis, Intermediate

Interventions: Drug: Sham Injector
Drug: FAI Insert

First Posted Date: 2021-10-07

Last Posted Date: 2024-12-19

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT05070728

Locations: 🇺🇸
EyePoint Study Site, Waltham, Massachusetts, United States

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Phase 1

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: EYP-1901

First Posted Date: 2021-02-10

Last Posted Date: 2023-07-19

Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Target Recruit Count: 17

Registration Number: NCT04747197

Locations: 🇺🇸
EyePoint Investigative Site, Asheville, North Carolina, United States
🇺🇸
EyePoint Investigational Site, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy